Point72 Asia (hong Kong) Ltd adds BioMarin Pharmaceutical (BMRN) to its portfolio

BioMarin Pharmaceutical (BMRN) : Point72 Asia (hong Kong) Ltd added new position in BioMarin Pharmaceutical during the most recent quarter end. The investment management firm now holds 10,051 shares of BioMarin Pharmaceutical which is valued at $929,114 , the company said in a statement filed on Aug 15, 2016 with the SEC.BioMarin Pharmaceutical makes up approximately 1.70% of Point72 Asia (hong Kong) Ltd’s portfolio.

Other Hedge Funds, Including , Highland Capital Management Lp reduced its stake in BMRN by selling 73,521 shares or 63.4% in the most recent quarter. The Hedge Fund company now holds 42,450 shares of BMRN which is valued at $3,924,078. BioMarin Pharmaceutical makes up approx 0.21% of Highland Capital Management Lp’s portfolio.Symphony Asset Management reduced its stake in BMRN by selling 190 shares or 3.3% in the most recent quarter. The Hedge Fund company now holds 5,575 shares of BMRN which is valued at $515,353. BioMarin Pharmaceutical makes up approx 0.09% of Symphony Asset Management’s portfolio. Fortaleza Asset Management Inc added BMRN to its portfolio by purchasing 35 company shares during the most recent quarter which is valued at $3,463.Jennison Associates boosted its stake in BMRN in the latest quarter, The investment management firm added 301,353 additional shares and now holds a total of 9,051,244 shares of BioMarin Pharmaceutical which is valued at $918,339,216. BioMarin Pharmaceutical makes up approx 0.96% of Jennison Associates’s portfolio.Shell Asset Management Co boosted its stake in BMRN in the latest quarter, The investment management firm added 5,179 additional shares and now holds a total of 27,415 shares of BioMarin Pharmaceutical which is valued at $2,689,137. BioMarin Pharmaceutical makes up approx 0.06% of Shell Asset Management Co’s portfolio.

BioMarin Pharmaceutical opened for trading at $93.7 and hit $95.49 on the upside on Thursday, eventually ending the session at $95.19, with a gain of 1.38% or 1.3 points. The heightened volatility saw the trading volume jump to 10,12,496 shares. Company has a market cap of $15,560 M.

On the company’s financial health, BioMarin Pharmaceutical reported $-2.61 EPS for the quarter, missing the analyst consensus estimate by $ -2.52 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.09. The company had revenue of $300.10 million for the quarter, compared to analysts expectations of $279.05 million. The company’s revenue was up 20.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.51 EPS.

Many Wall Street Analysts have commented on BioMarin Pharmaceutical. Company shares were Reiterated by Stifel on Aug 5, 2016 to “Buy”, Firm has raised the Price Target to $ 113 from a previous price target of $107 .Company shares were Reiterated by Piper Jaffray on Aug 5, 2016 to “Overweight”, Firm has raised the Price Target to $ 120 from a previous price target of $107 .

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company’s product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha) Naglazyme (galsulfase) Kuvan (sapropterin dihydrochloride) Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States the European Union. Aldurazyme which was developed in collaboration with Genzyme Corporation (Genzyme) was approved for marketing in the United States the European Union and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *